Anticoagulants in pregnancy: fetal effects

Area of Science:

• Obstetrics and Gynecology
• Hematology
• Pharmacology

Background:

• Anticoagulants are crucial for managing thromboembolic conditions in pregnant individuals.
• High-risk pregnancies necessitate careful consideration of anticoagulant therapy to prevent maternal and fetal complications.

Purpose of the Study:

• To review the safety and efficacy of different anticoagulant classes during pregnancy and breastfeeding.
• To compare the placental transfer and potential fetal effects of heparin versus oral anticoagulants.

Main Methods:

• Literature review of studies on anticoagulant use in pregnancy.
• Analysis of data on fetal outcomes associated with maternal anticoagulant therapy.
• Evaluation of safety profiles for heparin and oral anticoagulants in lactation.

Main Results:

• Unfractionated and low-molecular-weight heparin do not cross the placenta and are considered safe for fetal development.
• Oral anticoagulants cross the placenta, with documented associations with warfarin embryopathy, fetal central nervous system anomalies, and fetal hemorrhage.
• The precise incidence of these adverse fetal events from oral anticoagulants is not definitively established.
• Both heparin and oral anticoagulants are deemed safe for administration to nursing mothers.

Conclusions:

• Heparin anticoagulants represent a safer option for managing thromboembolic disorders during pregnancy.
• Careful patient selection and monitoring are essential when considering oral anticoagulants in pregnant individuals due to potential teratogenic effects.
• Anticoagulant therapy decisions during pregnancy require a thorough risk-benefit assessment for both mother and fetus.